Long-term commitment to manufacturing complex plasma-derived therapies in Europe, supplying patients in more than 100 countries as global demand grows.
Marburg, Germany, 19 November 2026 – Global biopharma leader CSL (ASX:CSL) today announced plans to invest approximately €610 million in its Marburg site through to 2030 to expand its capacity to produce critical medicines for people living with rare, chronic, and serious diseases.1 The investment is intended to strengthen the site’s role in health security and supply resilience across Europe, where many patients depend on these therapies for life.1-3.
Immunoglobulins and other plasma-derived therapies (PDTs) are essential for people with conditions such as primary immunodeficiencies (PIDs), haemophilia, and hereditary angioedema, and they are also used in emergency medicine, major surgery, and critical care.2,4-6 CSL manufactures complex plasma-derived and hyperimmune therapies at scale at its sites in Marburg and Bern (Switzerland).1
In FY2025/26, the Marburg site produced more than 18 million packs (finished, packaged units of medicine, such as a vial or syringe in a carton) and carried out around 5,000 production batch releases, supplying patients with PDTs and other therapies in more than 100 countries.1
CSL’s investment will fund two new filling lines with eight freeze dryers for PDTs.1 Once operational, which is expected in 2029, the new lines will further expand Marburg’s freeze-drying capacity.1 The investment will also fund a new bulk facility for fibrinogen, a plasma protein essential for blood clotting.1,7 Advanced facilities, automation, and digital process control support long-term manufacturing resilience and supply continuity.1
“This investment is about preparing Marburg for the future. By strengthening our manufacturing capabilities, we are reinforcing the site’s long-term role within CSL’s manufacturing network and our ability to reliably supply plasma-derived therapies to patients,” said Dr. Niklas Schier, VP, Site Head Marburg, CSL. “More than 300,000 patients in Europe depend on these therapies, and global demand continues to grow. With this investment, we are strengthening our biopharmaceutical manufacturing in Europe to deliver them here and around the world.”
Most plasma proteins cannot be made synthetically, so these therapies depend on donations from healthy volunteers.3-5,8,9 An estimated 130 donations are needed to treat one person with PID for a year, and around 1,200 for one person with severe haemophilia.4,9 Turning donated plasma into a finished therapy takes months of highly specialised manufacturing.5,8,9 PDTs therefore require sustained investment in both collection and manufacturing.3,9 Together with CSL Plasma’s donation centres, Marburg is part of an integrated network that connects donors to patients.3,10,11
“Every therapy we make in Marburg starts with a donation and ends with a patient. Plasma-derived therapies are fundamentally different from conventional pharmaceuticals because they depend on human donations, and a long, complex manufacturing process,” said Annegret Wittich-Hoeffer, VP and Cluster Head DACH, CSL. “As the EU works to strengthen the security of supply of critical medicines, our investment in the Marburg site contributes to a resilient European supply to ensure reliable access.”
The investment was announced at the ‘Marburg 2030 – Building What’s Next’ event at the site, attended by around 100 guests from politics, public administration, business, science, trade unions, and associations. CSL continues to work with stakeholders across Europe to support the manufacturing of PDTs in Europe.1
# ENDS #
About CSL
CSL (ASX:CSL; USOTC:CSLLY) is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis, and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs almost 29,000 people. Our unique combination of commercial strength, R&D focus, and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSL.com/Vita.
For more information about CSL, visit CSL.com.
Media contact
Martin Wans
Mobile: +49 151 200 36 422
Email: Martin.wans@cslbehring.com
References
1. CSL. Data on file. November 2026.
2. Plasma Protein Therapeutics Association (PPTA). Rare Diseases. Available from: https://www.pptaglobal.org/material/rare-diseases. Accessed: November 2026.
3. Wahl J, Haanperä T, Siersbæk N, Islam M, Nissen MT. The Impact of Plasma-Derived Therapies in Europe: The Health and Economic Case for Ensuring Sustainable Supply. Copenhagen Economics. 2026.
4. Plasma Protein Therapeutics Association (PPTA). Plasma Protein Therapies: Uniquely Saving Lives. Available from: https://www.uniquelysavinglives.org/plasma. Accessed: November 2026.
5. Kluszczynski T, Rohr S, Ernst R. Key Economic and Value Considerations for Plasma-Derived Medicinal Products (PDMPs) in Europe. Plasma Protein Therapeutics Association (PPTA). 2020.
6. Baskaran J, Lopez RA, Cassagnol M. Prothrombin Complex Concentrate. StatPearls Publishing. 2024.
7. European Medicines Agency. Guideline on Core SmPC for Human Fibrinogen Products. 2015.
8. Plasma Protein Therapeutics Association (PPTA). PPTA Welcomes European Parliament SANT Committee’s Approach to CMA Scope. Available from: https://www.pptaglobal.org/material/ppta-welcomes-european-parliament-sant-committees-approach-to-cma-scope. Accessed: November 2026.
9. Grabowski H, Manning R. Key Economic and Value Considerations in the US Market for Plasma Protein Therapies. Bates White Economic Consulting. 2018.
10. CSL. CSL Annual Report 2025/26. 2026.
11. CSL. One of the World's Largest Collectors of Human Plasma. Available from: https://www.csl.com/we-are-csl/our-businesses-and-products/csl-behring/csl-plasma. Accessed: November 2026.


